online opt-in

Echelon Insights

Echelon Insights May 2022 Verified Voter Omnibus · May 20–23, 2022 · US national

Methodology

Pollster
Echelon Insights commercial
Sponsor
Echelon Insights
Fielded
May 20–23, 2022
Population
likely voters
Sample size
1,020
Sample frame
online opt-in
Mode
online sample from the Lucid sample exchange, matched to the L2 voter file
Margin of error
±3.7 percentage points
Weighting
not stated on the public topline beyond the voter-file match
Geography
US national

Sources

Verification note. Wording and percentages transcribed directly from the Echelon Insights Verified Voter Omnibus topline PDF harvested from echeloninsights.com. Net figures and component shares were cross-checked against each other (the two 'strongly/somewhat' components sum to the printed net) to confirm the column alignment survived PDF text extraction. Echelon's public toplines carry field dates, n and margin of error but no weighting statement and no party crosstabs; the separately published crosstab decks were not parsed for this sweep. For this grid row the Unsure column did not survive text extraction and is recorded as null; the five substantive shares plus the two printed nets are internally consistent (22+10=32 more, 9+18=27 less).

Figures below are transcribed from these documents. Where they disagree with the source, the source governs.

Questions asked (1)

Adult medical care5-point scalein a trend series
whether hormone therapy for transgender individuals should be more or less regulated by government

Do you think think there should more government regulation, less government regulation, or about the same amount of regulation as now of each of the following? [DISPLAY AS GRID] [RANDOMIZE ROWS] [RANDOMIZE SCALE 1-5, 5-1] [DISPLAY OVER 2 PAGES] (the doubled word 'think think' is in the original topline)

Hormone therapy for transgender individuals

Much more
22%
The same
22%
Much less
18%
Somewhat more
10%
Somewhat less
9%
More regulation (net) 32%Less regulation (net) 27%

Wording notes: gender-affirming hormone therapy is placed in a consumer/industry regulation grid alongside social media, large tech companies, medical insurance, marijuana and business in general, which frames a medical treatment as a market activity | no distinction between adults and minors | 'more regulation' is ambiguous - it can mean safety oversight or prohibition

unclear — the scale itself is symmetric and neutral, but the response cannot be interpreted cleanly: a respondent wanting stronger clinical safeguards and one wanting an outright ban both answer 'much more regulation', and placing the item next to marijuana and abortion supplies a moral-regulation frame the wording does not state

Every figure on this page is transcribed from the source linked above. How to read this data →